MediMergent has announced the use of its digital clinical trials platform to collect and analyse real-world data (RWD) in a multicentre Engaging Immuno-Protection Intervention Study (EIMPRIS).
The study is focused on preventing symptomatic SARS-CoV-2 infection in cancer patients.
It is using MediMergent’s new methodology and artificial intelligence for capturing the voice of the patient (VOP) by using the data collection instruments and comparing them with the other (proxy) sources, including pharmacy, claims data, and patient medical records.
EIMPRIS will measure how RWD impacts treatment and outcomes, when integrated with the data related to quality of life, social determinants of health (SDoH), as well as other behavioural and attitudinal data.
MediMergent stated that its platform also works as a trial management system.
It engages with patients directly and detects and alerts adverse events, tracks and monitors all the study related activities, and yields unprecedented data on the experience of patients.
MediMergent chief operating officer Bruce Garrett said: “We are pleased to partner with Aon as the sponsor of EIMPRIS in conjunction with leading community based oncology centres to engage the VOP.
“The implementation of our RWD model in this large, investigator initiated program demonstrates MediMergent’s ability to efficiently and economically collect, track and analyse high quality patient related data.
“Our novel approach to clinical trial management and data aggregation improves patient enrolment, speeds up data input, and allows for earlier evaluation of results.”
